Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...

In October, the Centers for Disease Control and Prevention recommended that high-risk adults get a second updated Covid ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Sen. Rand Paul pointed to CDC guidance on child COVID-19 vaccinations, suggesting that people are "hesitant to believe" the ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Pfizer's RSV rollback comes as the space has grown increasingly crowded. Besides marketed vaccines, Sanofi and AstraZeneca sell an antibody to protect infants, with Merck & Co. now eying a piece of ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...